LIFE science business Optibiotix has reported the sale of its probiotic capsules to pharmacies in Germany.

York-based Optibiotix Health, which develops compounds to tackle obesity, high cholesterol, diabetes and skin care, has achieve product registration for its LPLDL capsules, through HLH BioPharma Vertriebs GmbH (HLH), with which it has a three year supply agreement.

HLH will market capsules containing LPLDL under the brand name Lactobact LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform.

Stephen O’Hara, chief executive of OptiBiotix, said: “We are pleased to see the first sales of our LPLDL strain in products available in Germany. We hope this will be the first of many product launches.”